In:
International Journal of Cancer, Wiley, Vol. 150, No. 4 ( 2022-02-15), p. 705-717
Abstract:
What's new? Because of the complexity and heterogeneity of breast tumours, the current prognostic markers have a limited prediction power. This retrospective observational study showed that high expression of the reductase GILT was associated with improved outcomes in a training set of 416 breast cancer patients and an independent validation set of 210 patients. GILT overexpression inhibited breast cancer cell proliferation, motility, and tumour formation in nude mice and increased breast cancer cell sensitivity to treatment by suppressing reactive oxygen species and autophagy. The results identified GILT as a novel prognostic biomarker that can effectively predict the prognosis of breast cancer patients.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink